Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: con.

Himmelfarb J, Szczech LA.

J Am Soc Nephrol. 2009 Jul;20(7):1441-3. No abstract available.

3.

Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting.

Winkelmayer WC.

J Am Soc Nephrol. 2011 Jan;22(1):1-2. doi: 10.1681/ASN.2010111133. Epub 2010 Dec 16. No abstract available.

4.

Does TREAT give the boot to ESAs in the treatment of CKD anemia?

Singh AK.

J Am Soc Nephrol. 2010 Jan;21(1):2-6. doi: 10.1681/ASN.2009111127. Epub 2009 Dec 24. No abstract available.

5.

[Regarding the optimal hemoglobin target range in renal anemia].

Maurin N.

Med Klin (Munich). 2008 Sep 15;103(9):633-7. doi: 10.1007/s00063-008-1102-3. Epub 2008 Sep 24. Review. German.

PMID:
18813886
6.

Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.

Sobota JT.

Contrib Nephrol. 1989;76:166-78; discussion 212-8. No abstract available.

PMID:
2684519
7.

Target hemoglobin level for EPO therapy in CKD.

Parfrey PS.

Am J Kidney Dis. 2006 Jan;47(1):171-3. No abstract available.

PMID:
16377399
8.

The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.

Singh AK.

Clin J Am Soc Nephrol. 2010 Apr;5(4):553-6. doi: 10.2215/CJN.00490110. Epub 2010 Mar 4. No abstract available.

9.

Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?

Walker RG.

Clin J Am Soc Nephrol. 2008 Jul;3(4):935-7. doi: 10.2215/CJN.02300508. Epub 2008 Jun 25. No abstract available.

10.

The treatment of anemia in chronic kidney disease: understandings in 2006.

Levin A.

Curr Opin Nephrol Hypertens. 2007 May;16(3):267-71. Review.

PMID:
17420672
11.

[Renal anemia treatment and outcome of patients with chronic kidney disease].

Kuragano T, Nakanishi T.

Nihon Jinzo Gakkai Shi. 2009;51(7):852-6. Review. Japanese. No abstract available.

PMID:
19928557
12.

Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate.

Agarwal R.

Clin J Am Soc Nephrol. 2010 Jul;5(7):1340-6. doi: 10.2215/CJN.02830310. Epub 2010 May 6.

13.

What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?

Singh AK.

Curr Opin Nephrol Hypertens. 2010 Sep;19(5):420-4. doi: 10.1097/MNH.0b013e32833cf1d6. Review.

PMID:
20689425
14.

Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease.

Vaziri ND, Zhou XJ.

Nephrol Dial Transplant. 2009 Apr;24(4):1082-8. doi: 10.1093/ndt/gfn601. Epub 2008 Nov 5. No abstract available.

PMID:
18987263
15.

[A hematocrit greater than 36 lessens mortality and hospitalization in hemodialysis].

Fernández-Gallego J, Gutiérrez C.

Nefrologia. 2003;23(2):177-8. Spanish. No abstract available.

16.

Cardiorenal anemia syndrome in chronic kidney disease.

Tarng DC.

J Chin Med Assoc. 2007 Oct;70(10):424-9. Review.

17.

[CERA: Continuous Erythropoietin Receptor Activator for anemia in CKD patients].

Cozzolino M.

G Ital Nefrol. 2009 Jan-Feb;26(1):8. Italian. No abstract available.

PMID:
19255955
18.

Triumph and tragedy: anemia management in chronic kidney disease.

Novak JE, Szczech LA.

Curr Opin Nephrol Hypertens. 2008 Nov;17(6):580-8. doi: 10.1097/MNH.0b013e32830c488d. Review.

PMID:
18941350
19.

The effect of ultrapure dialysate on improving renal anemia.

Go I, Takemoto Y, Tsuchida K, Sugimura K, Nakatani T.

Osaka City Med J. 2007 Jun;53(1):17-23.

PMID:
17867630
20.

[Anemia: guidelines comparison].

Del Vecchio L.

G Ital Nefrol. 2009 Nov-Dec;26(6):686-94. Italian.

PMID:
19918751

Supplemental Content

Support Center